Skip to content

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
CTO
Citius Oncology, Inc.CTOR
0.1×+0.1×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.5×+1.3×
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
19.8×+14.9×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.4×+4.3×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s quick ratio?
TuHURA Biosciences, Inc. (HURA) reported quick ratio of 1.2× in Q1 2026.
How has TuHURA Biosciences, Inc.'s quick ratio changed year-over-year?
TuHURA Biosciences, Inc.'s quick ratio decreased by 61.6% year-over-year, from 3× to 1.2×.
What is the long-term trend for TuHURA Biosciences, Inc.'s quick ratio?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s quick ratio has grown at a -34.9% compound annual growth rate (CAGR), from 2.8× to 0.8×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.